Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-03446962 plus best supportive care versus best supportive care in advanced hepatocellular carcinoma
2013-001426-26Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing PF-03446962 plus best supportive care with Best supportive care alone (2 arms). Primary endpoint: Overall survival. Started Apr 2014; status: terminated.
02
Drugs
ascrinvacumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2013-001426-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001426-26.